CTOs on the Move

Innovative Cellular Therapeutics

www.ictbio.com

 
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ictbio.com
  • 1405 Research Boulevard Suite 210
    Rockville, MD USA 20850
  • Phone: 240.690.9110

Executives

Name Title Contact Details

Similar Companies

ISK Biosciences Corporation

ISK Biosciences Corporation is a Painesville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Recor Medical

The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...

Centric Health Resources

Centric Health Resources is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NLS Pharmaceutics

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity.

SHINE Technologies

Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE`s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy`s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth